PT3151832T - Métodos para aumentar a inibição tónica e tratar a insónia secundária - Google Patents

Métodos para aumentar a inibição tónica e tratar a insónia secundária

Info

Publication number
PT3151832T
PT3151832T PT158033647T PT15803364T PT3151832T PT 3151832 T PT3151832 T PT 3151832T PT 158033647 T PT158033647 T PT 158033647T PT 15803364 T PT15803364 T PT 15803364T PT 3151832 T PT3151832 T PT 3151832T
Authority
PT
Portugal
Prior art keywords
methods
treating secondary
tonic inhibition
secondary insomnia
increasing tonic
Prior art date
Application number
PT158033647T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of PT3151832T publication Critical patent/PT3151832T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PT158033647T 2014-06-06 2015-06-03 Métodos para aumentar a inibição tónica e tratar a insónia secundária PT3151832T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06

Publications (1)

Publication Number Publication Date
PT3151832T true PT3151832T (pt) 2021-06-15

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
PT158033647T PT3151832T (pt) 2014-06-06 2015-06-03 Métodos para aumentar a inibição tónica e tratar a insónia secundária
PT181692112T PT3372229T (pt) 2014-06-06 2015-06-03 Métodos para aumentar a inibição tónica e tratar a síndrome de angelman

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181692112T PT3372229T (pt) 2014-06-06 2015-06-03 Métodos para aumentar a inibição tónica e tratar a síndrome de angelman

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3795156A1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124366T1 (enExample)
DK (2) DK3151832T3 (enExample)
ES (2) ES2875742T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX391502B (enExample)
PL (2) PL3151832T3 (enExample)
PT (2) PT3151832T (enExample)
RS (2) RS62007B1 (enExample)
SI (2) SI3151832T1 (enExample)
SM (2) SMT202100343T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3065782B8 (en) 2013-11-05 2021-05-26 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) * 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
AU2024220869A1 (en) 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
EP3795156A1 (en) * 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
US20160038469A1 (en) 2016-02-11
JP2021178836A (ja) 2021-11-18
EP3151832A1 (en) 2017-04-12
IL249287B (en) 2021-03-25
MX2020012404A (es) 2022-04-11
US20170071917A1 (en) 2017-03-16
LT3372229T (lt) 2021-07-12
AR100772A1 (es) 2016-11-02
JP2020063264A (ja) 2020-04-23
CY1124366T1 (el) 2022-07-22
PT3372229T (pt) 2021-06-17
US20180015076A1 (en) 2018-01-18
DK3372229T3 (da) 2021-06-14
US20250025448A1 (en) 2025-01-23
SI3151832T1 (sl) 2021-08-31
MX380868B (es) 2025-03-12
AU2020217342B2 (en) 2021-10-07
IL268960B (en) 2021-05-31
US11278529B2 (en) 2022-03-22
US9339495B2 (en) 2016-05-17
IL249287A0 (en) 2017-02-28
IL268960A (en) 2019-10-31
HRP20210901T1 (hr) 2021-09-17
CY1124368T1 (el) 2022-07-22
WO2015187851A1 (en) 2015-12-10
US9744159B2 (en) 2017-08-29
SMT202100343T1 (it) 2021-07-12
EP3372229B1 (en) 2021-03-24
US20170087133A1 (en) 2017-03-30
HRP20210902T1 (hr) 2021-09-17
ES2875742T3 (es) 2021-11-11
US20230051859A1 (en) 2023-02-16
AU2020217342A1 (en) 2020-08-27
CA2950845C (en) 2023-04-25
CA2950845A1 (en) 2015-12-10
LT3151832T (lt) 2021-07-12
MX2016016136A (es) 2017-07-05
ES2876350T3 (es) 2021-11-12
AU2015269667A1 (en) 2016-12-22
AU2024202604A1 (en) 2024-05-09
HUE055155T2 (hu) 2021-11-29
US20220016091A1 (en) 2022-01-20
EP3151832B1 (en) 2021-03-24
US9801864B2 (en) 2017-10-31
US20180303805A1 (en) 2018-10-25
JP2023123442A (ja) 2023-09-05
RS62007B1 (sr) 2021-07-30
PL3372229T3 (pl) 2021-10-04
SMT202100340T1 (it) 2021-07-12
AU2015269667B2 (en) 2020-07-30
JP2017516868A (ja) 2017-06-22
SI3372229T1 (sl) 2021-09-30
US20160228418A1 (en) 2016-08-11
RS62006B1 (sr) 2021-07-30
PL3151832T3 (pl) 2021-10-25
EP3795156A1 (en) 2021-03-24
HUE055400T2 (hu) 2021-11-29
AU2022200085A1 (en) 2022-02-03
DK3151832T3 (da) 2021-06-14
US9446028B2 (en) 2016-09-20
US20170273956A1 (en) 2017-09-28
MX391502B (es) 2025-03-21
EP3151832A4 (en) 2018-01-17
US20150352085A1 (en) 2015-12-10
EP3372229A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
IL249287A0 (en) Methods for increasing tonic inhibition and treating secondary insomnia
IL283799B (en) Compounds and methods for the treatment of RNA-mediated diseases
ZA202006746B (en) Methods of treatment
GB2557123B (en) Modified cells and methods of therapy
IL267291B (en) Actonucleotidase inhibitors and methods of using them
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
IL259801A (en) ezh2 inhibitors and methods of using them
PL3548033T3 (pl) Związki i sposoby ich stosowania
SG10201802098UA (en) Compositions and methods of use for treating metabolic disorders
IL251759A0 (en) Preparations and methods for treating insomnia
IL254273A0 (en) Variants of protoxin-ii and methods of use
LT3661510T (lt) Elgesio pakitimų gydymo būdai
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201621737D0 (en) Compositions and methods of treatment
GB201605127D0 (en) Composition and methods of treatment
HUE058190T2 (hu) Enoláz inhibitorok és ezekkel történõ kezelési eljárások
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201702189D0 (en) Theory of time and energy
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201510576D0 (en) Implants and methods of forming thereof
GB201522955D0 (en) Devices and methods for anaerobic treatment of wastewater
GB201421511D0 (en) Methods of screening and treatment
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases